Scribe, Vertex add to gene therapy's advance with $1B+ deal, near-term BLA
BioWorld
|
September 27, 2022
X min read
BioWorld
|
September 27, 2022
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
